Li Ying, Tang Jin-Hai, Huang Xin-En, Li Chen-guang
Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Nanjing, China.
Asian Pac J Cancer Prev. 2011;12(7):1795-8.
To compare the safety and efficacy of a combination of 5-Fu, pirarubicin and CTX (FPC) with FEC as a postoperative adjuvant chemotherapy for breast cancer.
A total of 655 breast cancer patients were treated postoperatively in Jiangsu Cancer Hospital and Research Institute from 1995-2005, 292 were treated with FPC (5-Fu 500 mg/m2 i.v. gtt on day 1, pirarubicin 40 mg/m2 i.v. on day 1, CTX 500 mg/m2 i.v. on day 1 and a cycle repeated every 21-28 days for totally 4-6 cycles); 363 with FEC (5-Fu 500 mg/m2 i.v. gtt on day 1, epirubicin 50 mg/m2 i.v. on day 1 and day 2, CTX 500 mg/m2 i.v. on day 1 and a cycle repeated every 21-28 days for totally 4-6 cycles). Toxicity was evaluated after each cycle of chemotherapy.
Main side effects in both FPC and FEC groups were leukopenia and gastrointestinal toxicity, with a 5 year survival rate 88.7% in FPC and 85.7% in FEC group.
FPC regimen is safe with superior long-term survival rate when compared with FEC, thus could be recommended as a postoperative chemotherapy regimen for Chinese patients with breast cancer.
比较5-氟尿嘧啶、吡柔比星和环磷酰胺联合方案（FPC）与氟尿嘧啶、表柔比星和环磷酰胺联合方案（FEC）作为乳腺癌术后辅助化疗的安全性和疗效。
1995年至2005年期间，江苏省肿瘤医院和研究所共对655例乳腺癌患者进行了术后治疗，其中292例接受FPC方案治疗（5-氟尿嘧啶500mg/m²静脉滴注，第1天；吡柔比星40mg/m²静脉注射，第1天；环磷酰胺500mg/m²静脉注射，第1天，每21 - 28天重复1个周期，共4 - 6个周期）；363例接受FEC方案治疗（5-氟尿嘧啶500mg/m²静脉滴注，第1天；表柔比星50mg/m²静脉注射，第1天和第2天；环磷酰胺500mg/m²静脉注射，第1天，每21 - 28天重复1个周期，共4 - 6个周期）。每个化疗周期后评估毒性反应。
FPC组和FEC组的主要副作用均为白细胞减少和胃肠道毒性，FPC组5年生存率为88.7%，FEC组为85.7%。
与FEC方案相比，FPC方案安全且长期生存率更高，因此可推荐作为中国乳腺癌患者的术后化疗方案。
